Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
Based on next generation of hybridoma technology, we could successfully generate stereospecific monoclonal antibodies (ssmAbs) against stress-related human CRHR1, which belongs to one of GPCRs. After Cell-ELISA positive hybridoma cells were cloned by limiting dilution method, not only IgM-typed but also IgG-typed ssmAbs were obtained. Furthermore, this new technology was applicable to selective production of ssmAbs against other GPCR. Immunofluorescence analysis demonstrated that ssmAb specifically recognized intact hCRHR1 on the cell surface.
|